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Abstract
Background: Paraneoplastic movement disorders in prostate cancer are rare, and to our knowledge paraneoplastic myoclonus has not previously been reported.
Case Report: We report two men with adenocarcinoma of the prostate who developed isolated alcohol-responsive action myoclonus of one leg. Myoclonus was
absent at rest but triggered by movement, standing, or walking. Evaluations excluded malignant invasion of the nervous system, and testing for commercial
paraneoplastic antibodies in serum and cerebrospinal fluid were unrevealing. Both patients experienced significant improvement with alcohol, and sodium oxybate
was used in one patient with good initial benefit.
Discussion: Alcohol-responsive leg myoclonus might be a novel paraneoplastic syndrome associated with prostate cancer. The nature of the syndrome and the
source of the myoclonus are currently unknown.
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Introduction
Neurologic complications of prostate cancer may be related
directly to the cancer, to metastatic disease, or to the side effects of
treatment. Paraneoplastic syndromes associated with prostate cancer
are quite rare, and include endocrinologic, hematologic, dermatolo-
gic, inflammatory, hepatobiliary, and neurologic syndromes.1
Neurologic paraneoplastic movement disorders (PMDs) associated
with prostate cancer are even rarer, and these include ataxia
secondary to paraneoplastic cerebellar degeneration, ataxia asso-
ciated with limbic encephalitis, and myoclonus in limbic encephalitis
and brainstem syndromes.
Here we describe two very unusual patients with prostate cancer,
with remarkably similar alcohol-responsive unilateral leg action
myoclonus. Alternative explanations for this unusual movement
disorder (metastatic disease, known paraneoplastic syndrome) were
excluded. We propose the possibility that these patients represent a
novel paraneoplastic syndrome associated with prostate cancer.
Case reports
Patient 1
A 74-year-old man was diagnosed with prostate cancer in 2010
and underwent an uncomplicated laparoscopic prostatectomy.
Histopathologic examination revealed adenocarcinoma, and abir-
aterone acetate in combination with prednisone was started for
treatment. Three weeks after surgery, he became aware of jerking
movements of the left foot and ankle triggered by movement or
weight bearing. Two months after surgery he developed similar
jerking of the right proximal leg, which then became much more
prominent. Movements were triggered by moving the right leg
against resistance and by walking, requiring use of a walker. On
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examination, muscle tone, strength, sensation, and reflexes were
normal, and there was no myoclonus at rest or with stimulus. On
attempting to use the right leg to resist the examiner or to stand, he
developed significant action myoclonus (Video 1, Segment 1), and he
could walk only with assistance. We did not observe myoclonus of
the left leg. An extensive evaluation including magnetic resonance
imaging (MRI) of the brain and total spine, serum erythrocyte
sedimentation rate (ESR), white blood cell and protein in
cerebrospinal fluid (CSF; personal communication with his outside
neuro-oncologist and neurologist), CSF studies for malignancy, and
commercially available paraneoplastic antibody testing was unre-
markable. An overnight ambulatory electroencephalography (EEG)
was also normal. Intravenous steroids (methylprednisolone 1 g/day
for a total of 5 days) produced a transient benefit in myoclonus, but
intravenous immunoglobulin (IVIG; 2 g/kg/course) did not help at
all. A combination of levetiracetam (2,000 mg/day) and clonazepam
(0.5 mg/day; he developed sedation at higher doses) provided only
modest benefit.
He discovered on his own that the movements were attenuated
when drinking alcohol, and in fact reported that he was able to walk
without using his walker when he ingested two stiff drinks of Scotch.
This fact prompted us to start sodium oxybate as a symptomatic
therapy (titrated up to 3 g/day), with moderate improvement noted in
a dose-dependent fashion (Video 1, Segment 2). Four years after his
original diagnosis he eventually succumbed to metastatic prostate
cancer.
Patient 2
A 76-year-old male presented for evaluation of involuntary move-
ments of the left leg. He had been diagnosed with metastatic
Video 1. Patient 1 before and 1 Month after Initiation of Sodium
Oxybate. Segment 1. Pre-sodium Oxybate. The examination in Segment
1 was performed 2 years after the onset of myoclonus. In this segment,
myoclonus of the right leg, not present at rest, emerged when the patient
stretched his leg out in a seated position. The myoclonus was prominent and
mainly generated from the proximal leg. It was also present when standing and
walking, and limited his ability to perform these activities. Bearing weight on the
right foot (such as when standing on the right foot only) also triggered the
myoclonus. After this visit, sodium oxybate was initiated and titrated up to 1.5 g
twice a day. He had moderate benefit in dose-dependent fashion (not shown in
the video at the lower dose). Segment 2. After Initiation of Sodium
Oxybate. Segment 2 demonstrates Patient 1 after taking sodium oxybate for 1
month. The examination was performed 2 hours after the last dose. Myoclonic
jerks of the right leg were moderately improved, and his ability to perform daily
activities improved as well. He was able to walk independently, but still required
his wife by his side due to fear of falling.
Video 2. Patient 2. Segment 1. The Examination Performed 1 Year
after the Onset of Myoclonus (2 Years after the Diagnosis of
Prostate Cancer). There was no myoclonus at rest. When he pushed the left
thigh or extended the left knee against the examiner’s hand, prominent
myoclonic jerks of the left leg emerged, especially from the proximal region
around the hip joint. In one part of the video, he attempted to counter the jerks
with his right leg. Upon arising from the chair and standing, myoclonic jerks of
the left proximal leg became prominent leading to difficulty performing these
activities and walking. Segment 2. Home Video Demonstrating Walking
Immediately after Ingesting Two Glasses of Wine. Although walking
with his walker, mild intermittent myoclonus of the left leg, mainly generated
from the proximal region, was present; however, he was able to ambulate.
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adenocarcinoma of the prostate with diffuse bony metastases 2 years
previously and had been treated with leuprolide. He did not undergo
any surgical intervention or local radiation. One year after the cancer
diagnosis, he developed involuntary jerking movements of the left leg,
especially around the hip joint. Movements were triggered by moving
the leg when seated, and especially by attempting to stand. Because of
the severity of the movements he was confined to a wheelchair for 6
months. Imaging of the spine and CSF examination revealed no
evidence of metastatic disease. Serum ESR and CSF white blood cell
count and protein were within normal limits (personal communication
with his outside neuro-oncologist and neurologist). Serum and CSF
commercial testing for known paraneoplastic antibodies was negative.
He had been treated with IVIG 2 g/kg/course) without apparent
benefit. On examination, there was no myoclonus at rest or with
stimuli. Violent action myoclonus of the left leg was generated when he
attempted to move the leg while in the chair, and was especially
noticeable when he tried to stand (Video 2, Segment 1). His neurologic
examination was otherwise notable only for 3+ reflexes in both knees
and ankles with crossed adductor signs.
Given our prior therapeutic experience in Patient 1, we suggested
that he try a small amount of alcohol to evaluate his level of response.
His myoclonus was markedly improved with alcohol (Video 2,
Segment 2). Unfortunately, we were unable to obtain insurance
approval for sodium oxybate, and a therapeutic trial could not be
attempted.
Discussion
We present two unusual patients with almost identical phenomen-
ologies in the setting of prostate cancer. Common clinical features
included unilateral action myoclonus of one leg triggered by move-
ments such as standing or walking. Both patients experienced
significant improvement with alcohol, and sodium oxybate was used
in one patient (up to 3 g/day) with good initial benefit. Patient 1 also
tried a combination of levetiracetam 2,000 mg/day and clonazepam
1.25 mg/day with only modest benefit, intravenous methylpredniso-
lone 1 g/day for a total of 5 days with only transient benefit, and IVIG
2 g/kg/course without benefit. Extensive work up for neoplastic or
known paraneoplastic syndromes was negative. No clear evidence of
inflammation in serum or CSF was found in our patients.
We postulate that the myoclonus in our patients was likely spinal in
origin. Although electrophysiologic testing was not available, their
clinical features support this possibility. Myoclonus that is localized to
only one limb, affects the leg, is proximal rather than distal, and is
stimulus-insensitive supports a spinal rather than a cortical origin. In
addition, there were no associated cortical findings on examination.
The distribution of myoclonus did not follow a nerve root or peripheral
nerve pattern, and the relatively widespread distribution of muscles
involved argues against a peripheral generator in a root or plexus
trunk.
An interesting clinical feature in our patients was their robust
response to alcohol. While immunotherapies were disappointing,
myoclonus in both patients markedly improved immediately after
drinking alcohol. This may be attributed to alcohol’s enhancement of
the effect of c-aminobutyric acid, a major inhibitory neurotransmitter.2
Of note, alcohol responsivity is a feature of other forms of subcortical
myoclonus, including myoclonus–dystonia syndrome (DYT11) and
subcortical posthypoxic myoclonus, as well as essential tremor and
spasmodic dysphonia, among others.3–5 Administration of sodium
oxybate, a derivative of c-hydroxybutyric acid, as a symptomatic
therapy in alcohol-responsive movement disorders has been studied.3–5
Patient 1 had moderate improvement noted in a dose-dependent
fashion.
While we cannot prove a paraneoplastic etiology, we believe that it
is unlikely that the identical phenotypes and histories of prostate cancer
in our patients are coincidental. The myoclonus in Patient 1 is not well
explained as a surgical-related complication for several reasons: 1) the
laparoscopic surgery was uncomplicated and the site of surgery was
relatively distant from the lumbar plexus, nerve roots, or spinal cord; 2)
the onset of myoclonus was subacute (3 weeks after the surgical
procedure), rather than acute in the immediate postoperative period;
3) Patient 2 with identical phenotypes had not undergone any previous
prostate surgery. Although focal neuropathies or neurapraxia involving
the ulnar, median, obturator, and femoral nerves, as well as the
lumbosacral plexus have been reported after laparoscopic prostatect-
omy,6–8 the subacute presentation and distribution of myoclonus in
Patient 1 argues against these causes.
Of note, a focal neurologic presentation does not exclude the
possibility of paraneoplastic etiology as demonstrated in several
reports, for example, in cases of paraneoplastic spinal segmental
myoclonus or paraneoplastic stiff limb syndrome.9,10 To our knowl-
edge, myoclonus has never been reported to be a side effect of
abiraterone acetate or leuprolide. In addition, there was no clear
temporal relationship between the initiation of these medications and
the onset of myoclonus in our patients. The other medications in
Patient 1 including levetiracetam and clonazepam are in fact anti-
myoclonic agents, and unlikely to cause myoclonus.
Lack of evidence of inflammation in the CSF also does not exclude
the possibility of paraneoplastic neurologic syndrome. Psimaras et al.11
found no inflammatory CSF in 7% of 295 patients in their series.
Malter et al.12 described 123 of 304 and 89 of 298 patients with
selected autoimmune neurologic syndromes in their series. Although
serum ESR is frequently checked in clinical practice in patients with
suspected paraneoplastic syndromes, it may not be a sensitive marker
for central nervous system (CNS) inflammation as the process may
confine to the CNS. N-methyl-D-aspartate (NMDA) encephalitis is one
example where evidence of the peripheral inflammatory process may
be absent on clinical investigations.13
Unfortunately, there is currently no true gold standard in the
diagnosis of paraneoplastic neurologic syndrome. Clinicians typically
confirm the diagnosis by the presence of previously described
antibodies, classic neurologic syndromes, and cancers.14 This method,
while it can be feasibly applied to clinical practice, may limit the
diagnosis of novel paraneoplastic syndromes. Immunopathological
identification of antigenic targets in a human brain or spinal cord may
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be performed on a research basis, but not in routine clinical practice.
With no proven gold standard or more immunological techniques to
confirm the paraneoplastic etiology in our cases, we would not
prematurely exclude the possibility of paraneoplastic neurologic
syndrome based on the lack of inflammatory evidence in the CSF
since this will limit the opportunity of further discovery of novel
antibodies related to this potential paraneoplastic syndrome.
PMDs associated with prostate cancer are reviewed in Table 1. The
most common neurologic complications of prostate cancer, 19% in
one large series,15 are due to metastasis to the vertebrae and their
neighboring structures through venous drainage of the lower
paravertebral plexus (Batson’s plexus) leading to spinal cord or nerve
root compression.16 Brain metastases are rare in prostate cancer.16
Paraneoplastic syndromes related to prostate cancer can involve
neurologic, endocrinologic, hematologic, inflammatory, and hepato-
biliary systems. Among the paraneoplastic neurologic syndromes
reported are limbic encephalitis, neuropathy (anti-Hu reported in one
case), brainstem syndromes, cerebellar degeneration, and Lambert–
Eaton myasthenic syndrome (LEMS) with or without cerebellar
degeneration (anti-voltage-gated calcium channel [anti-VGCC]
reported in LEMS with cerebellar degeneration).1 Antibodies to exact
targets were discovered in only some cases.
Two phenomenologies reported in the literature included ataxia
(with a greater number of reports) and myoclonus.17–26 Ataxia has
been reported in cerebellar syndromes, limbic encephalitis, and
brainstem syndromes.19–26 Myoclonus has been reported in one case
with a brainstem syndrome (another case in the same report with
“continuous muscle spasms”) and one with limbic encephalitis.17,18 Of
note, myoclonus is very rare in paraneoplastic syndromes with the
exception of opsoclonus–myoclonus syndrome and NMDA encepha-
litis.27
PMDs may be harbingers of prostate cancer. The neurologic
syndrome associated with the PMDs occurred up to 10 months before
the diagnosis of prostate cancer, and the most common tumor
histopathology was adenocarcinoma. Small cell carcinoma was
reported in one PMD case with paraneoplastic cerebellar degenera-
tion. While it has been stated that paraneoplastic syndromes are more
common in small cell-type carcinoma,28 our review showed that most
PMDs were associated with adenocarcinoma. A VGCC antibody was
found in a case with LEMS and cerebellar degeneration.20 Yo or
Purkinje cell cytoplasmic antibody type 1 and metabotropic glutamate
receptor 1 (mGluR1) and collapsing response mediator protein 5
(CV2/CRMP5) antibodies were found in three other patients with a
pure cerebellar syndrome.21–23 One patient with ataxia in the setting
of limbic encephalitis had positive anti-Hu antibody (or anti-neuronal
nuclear antibody 1, ANNA 1).25 An intraneuronal antibody was
identified in one patient with gait ataxia and a recurrent brainstem
syndrome; however, the exact antigen is unclear.26 Other patients did
not have antibodies that were identified. The failure to identify the
exact antigen in our cases does not exclude the possibility of a
paraneoplastic syndrome.
While treatment of the primary tumor is crucial, immunomodula-
tory therapies including IVIG, intravenous steroids, and plasma
exchange have also been used with variable success: poor responses in
cases with anti-Hu and anti-Yo (and our cases);21,25 initially good but
non-sustained responses in cases with anti-CV2/CRMP5 and
unidentified intraneuronal antibodies;23,26 and sustained responses in
cases with anti-mGluR1.22 These findings may indicate a poor
response for cell-mediated processes to intraneuronal/onconeuronal
antigens (such as Hu, Yo, and CV2/CRMP5), and a better response to
antibody-mediated processes to cell surface receptor antigens (such as
mGluR1).
For symptomatic treatment of myoclonus, diazepam and valproic
acid were employed in one brainstem syndrome case with moderate
benefit.17 Our patient (Patient 1) had modest benefit from a
combination of azathioprine, levetiracetam, and clonazepam. To our
knowledge, alcohol responsivity has never been reported in PMD
associated with prostate cancer. It is our hope that this paper will
engender future reports of similar phenomena.
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